TerminatedNCT04480554
Anti-retroviral Therapy, Medications for Addiction, Opioids and HIV Infection - Study 1
Medication studyAges 18–65United States + Vietnam
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Philadelphia and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 30, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 78
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Vietnam
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04480554
- Official title
Show the full official title
Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Philadelphia, United States · Ho Chi Minh City, Vietnam
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Does this study involve medication?
Yes. The study involves medication, including Methadone, Buprenorphine/naloxone and XR-Naltrexone.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
